Biopharmaceutical Amarin Corp. plc today is reporting positive, statistically significant top-line results from its first Phase 3 clinical trial of lead drug candidate AMR101, which is being investigated as a treatment for very high triglycerides.

Based in Dublin, Ireland, but with its R&D facilities in Mystic, Conn., Amarin (Nasdaq: AMRN) is a clinical-stage biopharmaceutical focused on cardiovascular disease.

SOURCE